10-Q: Krystal Biotech Reports Strong Q3 2024 Results Driven by VYJUVEK Sales

Krystal Biotech's Q3 2024 results show significant revenue growth driven by VYJUVEK sales, reaching $83.8 million for the quarter.

Summary

• Krystal Biotech reported a net product revenue of $83.8 million for the third quarter of 2024, a substantial increase compared to $8.6 million in the same period of 2023.
• The company's cumulative net product revenue since the launch of VYJUVEK has reached $250.1 million.
• Gross margin for the quarter was a strong 92%.
• Krystal Biotech achieved positive access determinations for 97% of lives covered under commercial and Medicaid plans in the U.S.
• Over 460 reimbursement approvals for VYJUVEK have been secured in the U.S. as of October 2024.
• Patient compliance with the once-weekly VYJUVEK treatment remains high at 87%.
• The company is preparing for direct commercial launches in Europe and Japan in 2025.
• A Marketing Authorization Application (MAA) for B-VEC is under review by the European Medicines Agency (EMA), with a CHMP opinion expected in Q4 2024.
• A Japan New Drug Application (JNDA) for B-VEC was filed in October 2024, with a decision expected in the second half of 2025.
• The company's cash, cash equivalents, and short-term investments totaled approximately $588.3 million as of September 30, 2024.
• Krystal Biotech believes its current cash position is sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth, high gross margins, and significant progress in regulatory approvals. The company's financial position is also robust. However, there are some risks and challenges mentioned, which prevent a perfect score.

Positives

• The company experienced substantial revenue growth driven by VYJUVEK sales.
• High gross margin of 92% indicates strong profitability on product sales.
• Excellent access and reimbursement coverage for VYJUVEK in the U.S.
• High patient compliance with VYJUVEK treatment suggests positive patient experience.
• Progress in regulatory approvals in Europe and Japan indicates potential for international expansion.
• Strong cash position provides financial stability for future operations.

Negatives

• Research and development expenses increased by $2.9 million in Q3 2024 compared to Q3 2023.
• Selling, general, and administrative expenses increased by $5.0 million in Q3 2024 compared to Q3 2023.
• Litigation settlement expenses were $12.5 million for Q3 2024.
• The company recorded an income tax expense of $2.6 million for Q3 2024.

Risks

• The company is substantially dependent on the commercial success of VYJUVEK.
• There are risks associated with the development and commercialization of additional product candidates.
• The company faces significant competition in the biotechnology industry.
• Product liability lawsuits could result in substantial liabilities.
• Negative public opinion or increased regulatory scrutiny of gene therapy could harm the company.
• The company's operations are subject to various healthcare fraud and abuse laws.
• The company is subject to stringent and evolving privacy and data security laws.
• The company's internal computer systems may be vulnerable to cyber-security incidents.
• The company's international operations expose it to various risks.
• The company is subject to U.S. and foreign export and import controls, anti-corruption laws and anti-money laundering laws and regulations.
• The company's operations could be adversely affected by pandemics, epidemics, outbreaks of infectious diseases, or similar public health crises.
• Inadequate funding for the FDA and other government agencies could hinder their ability to perform normal business functions.
• The company may experience delays in clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.
• The company relies on third parties to conduct certain of its preclinical studies or aspects of its preclinical studies and clinical trials.
• The company may encounter substantial delays in its clinical trials, or it may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.
• The company may not be able to obtain regulatory approvals for its product candidates outside of the United States.
• The company's product candidates that receive marketing approvals remain subject to regulatory oversight even after regulatory approval.
• The company may not be able to obtain or maintain orphan drug exclusivity for its product candidates.
• The company may not be able to obtain a priority review voucher for its product candidates.
• The company may not be able to obtain a designated platform technology designation for its platform technology.
• Delays in obtaining regulatory approvals of the process, or changes to the process, and facilities needed to manufacture VYJUVEK or its product candidates or disruptions in its manufacturing process may disrupt its production of VYJUVEK or delay or disrupt its development and commercialization efforts with respect to its product candidates.
• The company relies on a limited number of third-party suppliers for some of the components and materials used in manufacturing VYJUVEK and its product candidates.
• The company may need or desire to transfer VYJUVEK or an approved product candidate manufacturing from ANCORIS to ASTRA, or transfer an approved product manufacturing from ASTRA to ANCORIS, and technical transfer of a manufacturing process is subject to risks and uncertainties and requires FDA inspection and approval of the facility where manufacturing is planned to be transferred.
• The company has limited experience as a commercial company and the sales, marketing, and distribution of VYJUVEK or any future approved products may be unsuccessful or less successful than anticipated.
• If the company is unable to maintain its agreements with third parties to distribute VYJUVEK to patients in the United States, its results of operations and business could be adversely affected.
• The company plans on using local distributors to market and sell VYJUVEK in certain jurisdictions outside of the U.S., the U.K., certain EU countries, and Japan, which subjects it to certain risks.
• If the company is unable to expand its medical affairs, marketing, market access, sales, and distribution capabilities or collaborate with third parties to market and sell its product candidates for which it obtains marketing approval, it may be unable to generate sufficient product revenue.
• The company's efforts to educate the medical community and third-party payors on the benefits of VYJUVEK or its product candidates, if approved, may require significant resources and may never be successful.
• If VYJUVEK or any of its product candidates that are approved fails to achieve market acceptance among physicians, patients, or third-party payors, the company will not be able to generate significant revenue from such product, which could have a material adverse effect on its business, financial condition, results of operations, and prospects.
• If the market opportunities for VYJUVEK or its product candidates are smaller than the company believes they are, its product revenue may be adversely impacted, and its business may suffer.
• Government price controls or other changes in pricing regulation could restrict the amount that the company is able to charge for VYJUVEK and its product candidates, if approved, which would adversely affect its revenue and results of operations.
• The insurance coverage and reimbursement status of newly approved products is uncertain.
• Ethical, legal, and social issues related to genetic testing may reduce demand for the company's product candidates, if approved.
• Increasing demand for compassionate use or expanded access of the company's unapproved therapies could negatively affect its reputation and harm its business.
• If the company is unable to obtain and maintain adequate United States and foreign patent protection for VYJUVEK, its current product candidates, and any future product candidates it may develop, and/or its vector platform, or if the scope of the patent protection obtained is not sufficiently broad, its competitors could develop and commercialize products and technologies similar or identical to its, and its ability to successfully commercialize VYJUVEK, its current product candidates, any future product candidates it may develop, and its platform technologies may be adversely affected.
• Third parties may initiate legal proceedings alleging that the company is infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of its business.
• The company has been subject to claims asserting that it, its employees, or its advisors have wrongfully used or disclosed alleged trade secrets of other parties, and it may face such claims in the future or claims asserting ownership of what it regards as its own intellectual property.
• Changes in U.S. patent law could diminish the value of patents in general, thereby impairing the company's ability to protect VYJUVEK or its product candidates.
• If the company's trademarks and trade names are not adequately protected, then it may not be able to build name recognition in its markets of interest and its business may be adversely affected.
• The company's efforts to enforce or protect its proprietary rights related to patents, trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact its financial condition or results of operations.
• The company has incurred net losses in the past and may not sustain profitability.
• The company may need to raise additional funding to maintain and expand its commercialization capabilities and to complete the development of, and obtain the regulatory approvals necessary to, commercialize its product candidates.
• Changes in tax law may adversely affect the company's business and financial condition.
• The company's ability to use its net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation.
• The company's limited operating history may make it difficult for you to evaluate the success of its business to date and to assess its future viability.
• The company's Chief Executive Officer and Chairman of the Board of Directors and its Founder, President, Research & Development and Director will have the ability to substantially influence all matters submitted to stockholders for approval.
• If securities analysts publish negative evaluations of the company's stock, the price of its stock could decline.
• Raising additional capital could cause the price of the company's common stock to decline and cause dilution to its stockholders, restrict its operations or require it to relinquish rights.
• The price of the company's common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of its common stock.
• If the company fails to maintain effective internal control over financial reporting, it may not be able to accurately report its financial results, which may adversely affect investor confidence in its company and, as a result, the value of its common stock.
• Provisions in the company's corporate charter documents and under Delaware law could make an acquisition of it, which may be beneficial to its stockholders, more difficult and may prevent attempts by its stockholders to replace or remove its current management.
• The company has broad discretion in the use of its cash, cash equivalents, and marketable securities and may not use them effectively.
• Because the company does not anticipate paying any cash dividends on its common stock in the foreseeable future, capital appreciation, if any, will be stockholders sole source of gain.
• Issuing additional shares of the company's common stock could cause the price of its common stock to decline and cause dilution to its stockholders.
• If the company issues preferred stock in the future, the holders of that preferred stock could gain rights superior to its existing stockholders, such as liquidation and other preferences, or the market price of its common stock could be adversely affected.

Future Outlook

The company expects a CHMP opinion on the MAA for B-VEC in Europe in Q4 2024 and a launch in Germany in the first half of 2025. A decision on the JNDA for B-VEC in Japan is expected in the second half of 2025. The company plans to initiate the registrational IOLITE study for KB803 in the first half of 2025. The company expects to resume enrollment in the Phase 2 portion of JADE-1 in the first half of 2025. Jeune expects to initiate a Phase 2 study evaluating KB301 in the treatment of the dynamic wrinkles of the dcollet in 2025.

Management Comments

• Management intends to fund future operations through its on hand cash, cash equivalents and investments and revenue generated from the sale of VYJUVEK, and may also seek additional capital through the sale of equity, arrangements with strategic partners, debt financings or other sources.
• The Company believes that its cash, cash equivalents and short-term investments of approximately $588.3 million as of September 30, 2024 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q.

Industry Context

This announcement reflects the continued growth and commercial success of gene therapy products in the pharmaceutical industry. Krystal Biotech's progress with VYJUVEK and its pipeline candidates highlights the increasing potential of gene therapy to address unmet medical needs. The company's focus on rare diseases aligns with a broader industry trend towards developing treatments for niche patient populations.

Comparison to Industry Standards

• Krystal Biotech's 92% gross margin for VYJUVEK is significantly higher than the average for pharmaceutical products, which typically range from 60% to 80%. This indicates strong pricing power and efficient manufacturing processes.
• The company's rapid revenue growth from VYJUVEK sales is notable compared to other gene therapy launches, which often experience slower initial uptake due to the novelty of the treatment and the need for specialized administration.
• The high patient compliance rate of 87% for VYJUVEK is a positive indicator, as adherence to treatment regimens is a common challenge in chronic disease management. This suggests that the treatment is well-tolerated and convenient for patients.
• The company's progress in securing reimbursement approvals for 97% of covered lives in the U.S. is a strong performance compared to other companies launching new therapies, where reimbursement negotiations can be lengthy and challenging.
• The company's cash position of $588.3 million is robust compared to many other biotech companies of similar size, providing a solid financial foundation for continued development and commercialization efforts.
• The company's pipeline of gene therapy candidates is diverse, targeting multiple indications, which is a common strategy among biotech companies seeking to mitigate risk and maximize long-term growth potential.
• The company's in-house manufacturing capabilities are a significant advantage, as many biotech companies rely on third-party manufacturers, which can lead to supply chain vulnerabilities and higher costs. This is similar to companies like BioMarin and Vertex, which have invested heavily in their own manufacturing infrastructure.
• The company's regulatory progress in Europe and Japan is consistent with the timelines of other companies seeking global approvals for their therapies. The company's approach to commercialization in these regions is similar to that of other companies that have launched products in the U.S. and then expanded internationally.

Legal Proceedings

• The company is required to make a $6.25 million milestone payment to PeriphaGen within 120 days following December 31, 2024.
• The company is required to make a $12.5 million milestone payment to PeriphaGen within 30 days following the filing of its Annual Report on Form 10-K for the year ended December 31, 2024.
• The company is required to make a $12.5 million contingent milestone payment to PeriphaGen within 30 days following the filing of its Annual Report on Form 10-K that reports $300.0 million in cumulative sales.

Stakeholder Impact

• Shareholders will benefit from the strong revenue growth and positive financial outlook.
• Employees will benefit from the company's continued growth and success.
• Patients will benefit from the availability of VYJUVEK and the development of new therapies.
• Customers will benefit from the company's commitment to providing high-quality products and services.
• Suppliers will benefit from the company's continued growth and demand for their products and services.
• Creditors will benefit from the company's strong financial position and ability to meet its obligations.

Next Steps

• The company expects a CHMP opinion on the MAA for B-VEC in Europe in Q4 2024.
• The company plans to launch B-VEC in Germany in the first half of 2025.
• The company expects a decision on the JNDA for B-VEC in Japan in the second half of 2025.
• The company plans to initiate the registrational IOLITE study for KB803 in the first half of 2025.
• The company expects to resume enrollment in the Phase 2 portion of JADE-1 in the first half of 2025.
• Jeune expects to initiate a Phase 2 study evaluating KB301 in the treatment of the dynamic wrinkles of the dcollet in 2025.

Key Dates

Keywords

VYJUVEK, gene therapy, dystrophic epidermolysis bullosa, B-VEC, commercialization, regulatory approval, clinical trials, biotechnology, rare disease, manufacturing